NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory classroom study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Neos Therapeutics, Inc

Criteria

Inclusion Criteria:

• Currently being treated for ADHD

Exclusion Criteria:

• Other psychiatric diagnoses

• Significant cognitive impairment

• Chronic medical illnesses

• Structural cardiac defects

• Significant abnormal lab tests

• Taking disallowed medications

• Positive drug test